1. American Cancer Society. Cancer facts and figures 2007. http://www.cancer.org
2. V.T. DeVita, Jr., S.Hellman, S.A. Rosenberg. Cancer: Principles and Practice in Oncology, 2005, Lippincott Williams & Wilkins, Philadelphia PA USA
3. Neugut A et al: Epidemiology of colorectal adenomatous polyps. Cancer Epidemiol Biomarkers Prev 1993;2:159-176
4. Wilmink AB. Overview of the epidemiology of colorectal cancer. Dis Colon Rectum 1997;40:483
5. Ranshoff DF, Sandler RS. Clinical practice. Screening for colorectal cancer. N Engl J Med 2002;346:40-44
6. Walsh JM, Terdiman JP. Colorectal cancer screening: clinical applications. JAMA 2003;289:1279-1302
7. Ranshoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians. Ann Inter Med 1997;126:811-822
8. Bond JH. Fecal occult blood test screening for colorectal cancer. Gastrointest Endosc Clin N Am 2002;12:11-21
9. Winawer S et al. Gastrointestinal Consortium Panel. Colorectal cancer screening and surveillance: clinical guidelines and rationale – Update based on new evidence. Gastroenterology 2003 Feb; 124(2):544-60
10. ESGE workshop on colorectal cancer screening: Summary and outlook. Classen M. Endoscopy 2004, 36/4,366-368
11. Hiatt R et al. Workgroup IV: public education. UICC International Workshop on Facilitating Screening For Colorectal Cancer Ann Oncol 2005;16:38-41
12. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult blood testing and examination of the distal colon. N Engl J Med 2001;345:555-560
13. Hardcastle JD et al. Randomized controlled trial of fecal occult blood screening for colorectal cancer. Lancet 1996;348:1472-1477
14. Levin B et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58:130-160
15. Goodyear SJ et al. The effects of population-based faecal occult blood test screening upon emergency colorectal cancer admissions in Coventry and north Warwickshire. Gut 2008;57:218–222
16. Tsoi KK et al. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia. Alimentary Pharmacology & Therapeutics’ 2008; doi: 10.1111/j.1365-2036.2008.03726.x
17. Laghi A et al. Computed tomographic colonography (virtual colonoscopy): blinded perspective comparison with conventional colonoscopy for the detection of colorectal neoplasia. Endoscopy 2002;34:441-446
18. Pickhardt PJ et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003;349:2191-2200
19. Smith GA, O’Dwyer PJ. Sensitivity of double-contrast barium enema and colonoscopy for the detection of colorectal neoplasms. Surg Endosc 2001;15:649-652
20. Fearon ER and Vogelstein BA. Genetic model for colorectal tumorigenesis. Cell (1990) 61, 759–767
21. ASCO Subcommittee on Genetic Testing for Cancer Susceptibility. Statement of the American Society of Clinical Oncology. Genetic testing for cancer susceptibility. J Clin Oncol 1996;14:1730-1736
22. Tsoi KK et al. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia. Alimentary Pharmacology & Therapeutics’ 2008; doi: 10.1111/j.1365-2036.2008.03726.x
23. Lynch HT et al. Toward a Consensus in Molecular Diagnosis of Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome). J Natl Cancer Inst. 99 (4):261-3, 2007
24. Lagerstedt Robinson K et al. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst. 99(4):291-9, 2007
25. Vasen HF et al.Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet. 44(6):353-62, 2007
26. de la Chapelle A. Genetic Predisposition to Colorectal Cancer. Nature Review Cancer, 4:769, 2004
27. Balaguer F et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol. 5(3):379-87, 2007
28. Lynch HT, de la Chapelle A. Hereditary Colorectal Cancer, New England J Med, N Engl J Med 348:919, 2003
29. Lieberman DA et al, Five-Year Colon Surveillance After Screening Colonoscopy. Gastroenterology;133:1077-85, 2007. Imperiale TF. Toward Risk Stratification for Screening and Surveillance of Colorectal Neoplasia: One Small Step for the Colonoscopist. Gastroenterology;133:1364–1376, 2007
30. Nelson H et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001;93:583–96.
31. Goldberg RM et al. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med 1998;129(1):27-35.
32. Phillips RK et al. Local recurrence following “curative” surgery for large bowel cancer. I. The overall picture. Br J Surg 1984;71:12–6.
33. Panageas et al. The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med 2003;139:658–65.
34. Porter GA et al. Surgeon-related factors and outcome in rectal cancer. Ann Surg 1998;227:157–67.
35. The Clinical Outcomes of Surgical therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004;350:2050-2059.
36. Lowry AC et al. Consensus statement of definitions for anorectal physiology and rectal cancer: report of the Tripartite Consensus Conference on Definitions for Anorectal Physiology and Rectal Cancer, Washington, D.C., May 1, 1999. Dis Colon Rectum 2001;44:915–9.
37. Church J, Simmang C, Standards Task Force; American Society of Colon and Rectal Surgeons; Collaborative Group of the Americas on Inherited Colorectal Cancer and the Standards Committee of The American Society of Colon and Rectal Surgeons. Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer). Dis Colon Rectum 2003;46:1001–12.
38. Fong Y et al. Liver resection for colorectal metastases. J Clin Oncol 1997;15(3):938-946.
39. Rivoire M et al. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 2002;95(11):2283-2292.
40. Abdalla EK et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239(6):818-825; discussion 825-7.
41. Ambiru S et al. Resection of hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 1998;82(2):274-278.
42. Inoue M et al. Surgery for pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 2000;70(2):380-383.
43. Crooks S. Foresight that leads to improved outcome: stoma care nurses’ role in siting stomas. Prof Nurse 1994;10:89–92.
44. Fleshman JW et al. Accuracy of transrectal ultrasound in predicting pathologic stage of rectal cancer before and after preoperative radiation therapy. Dis Colon Rectum 1992;35:823–9.
45. Gibbs P et al. Optimizing the outcome for patients with rectal cancer. Dis Colon Rectum 2003;46:389–402.
46. MRC Rectal Cancer Working Party. Randomized trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Lancet 1996;348: 1610–4.
47. Kapiteijn E et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638–46.
48. Reynolds J et al. Pathological evidence in support of total mesorectal excision in the management of rectal cancer. Br J Surg 1996;83: 1112–5.
49. Barrier A et al. Long-term functional results of colonic J-pouch versus straight coloanal anastomosis. Br J Surg 1999;86:1176–9.
50. Kuvshinoff B et al. Distal margin requirements after preoperative chemoradiotherapy for distal rectal carcinomas: are ~1 cm distal margins sufficient? Ann Surg Oncol 2001;8:163–9.
51. Birbeck KF et al. Rates of circumferential margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg 2002;235:449–57.
52. De Haas-Kock et al. Prognostic significance of radial margins of clearance in rectal cancer. Br J Surg 1996;83:781–5.
53. Beets-Tan RG. MRI in rectal cancer: the T stage and circumferential resection margin. Colorectal Dis 2003; 5:392–5.
54. Young-Fadok TM et al. Prophylactic oophorectomy in colorectal carcinoma: preliminary results of a randomized, prospective trial. Dis Colon Rectum 1998;41:277–85
55. American Joint Committee on Cancer. Colon and rectum. 2002, Lippincott–Raven, Philadelphia PA, USA
56. Compton CC et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:979
57. LeVoyer TE et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003;21(15):2912-2919
58. Wolmark N et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with dukes’ B and C carcinoma of the colon: results from national surgical adjuvant breast and bowel project C-04. J Clin Oncol 1999; 17: 3553–3559
59. Benson A et al. American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 1–12
60. Twelves C et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696–2704
61. Douillard JY et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041–1047
62. de Gramont A et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–2947
63. Goldberg RM et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23–30
64. Tournigand C et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229–237
65. Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342
66. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet 2001; 358: 1291–1304
67. Sauer R et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731–1740
68. Folkesson J et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005; 23: 5644–5650